Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
RSVpreF has the potential to greatly reduce the public health and economic burden of RSV among older adults in Germany.
Authors
- Ahuva Averin (ORCID: https://orcid.org/0000-0002-4490-7021)
- Mark Atwood
- Reiko Sato (ORCID: https://orcid.org/0000-0003-2785-7103)
- Bennet Huebbe
- Christof von Eiff (ORCID: https://orcid.org/0000-0002-7821-2359)
- Caroline Lade
- Lea Johanna Bayer
Institutions
- Pfizer (United States) (US)
- Pfizer (Germany) (DE)
- Prevea Health (US)
- IGES Institut (DE)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/14760584.2024.2436183
- Citations
- 11
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 4.25
Funders
- Pfizer